JENBURKT PHARMACEUTICAL L (JENBURPH) financials

JENBURKT PHARMACEUTICAL L (JENBURPH) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

  • Market Cap: ₹421Cr.
  • Current Price: ₹954
  • Stock P/E: 11.8
  • ROE: 20.2%
  • ROCE: 27.0%
  • Book Value: ₹464
  • Dividend Yield: 2.17%
  • 52W High / Low: ₹1,297/845

In Sep 2026, JENBURKT PHARMACEUTICAL L (JENBURPH) reported sales ₹48 Cr and net profit ₹10 Cr.

Annual TTM: sales ₹171 Cr, net profit ₹33 Cr.

Shareholding: Promoters 46.62% (Sep 2026), DIIs 0.03% (Sep 2026), Public 53.34% (Sep 2026), No. of Shareholders 7,351% (Sep 2026).

JENBURPH quarterly results (₹ Cr.)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales3741364643453648
YoY Sales growth+3%+6%+9%+11%+17%+9%-0%+6%
Expenses2830273236302935
Operating Profit911913714613
OPM %24%26%25%29%17%32%17%27%
Other Income22222022
Interest00000000
Depreciation11111111
Profit before tax10121014814714
Tax %32%28%23%29%29%21%13%29%
Net Profit79810611610
EPS in Rs14.7519.3517.6523.0213.4424.5813.3523.13
Raw PDF————————
JENBURPH profit and loss (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales119109124137142152169171
Sales growth-3%-8%+13%+10%+4%+7%+11%+8%
Expenses998997106109111125131
Operating Profit2020273033404441
OPM %17%18%22%22%23%27%26%24%
Other Income44555766
Interest10000001
Depreciation22222333
Profit before tax2122303335444743
Tax %30%24%25%25%26%27%25%—
Net Profit1516222526323533
EPS in Rs32.4035.9548.5955.7658.8772.6478.7274.50
Dividend Payout %25%28%25%26%26%25%26%—
JENBURPH balance sheet (₹ Cr.)
CategoryMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital55544444
Reserves7594113118141167193201
Borrowings35730422
Other Liabilities2117181619192628
Total Liabilities104120143141164195225235
Fixed Assets1211111010151974
CWIP0001140463
Investments4781117212730
Other Assets88103123119136120132128
Total Assets104120143141164195225235
JENBURPH cash flows (₹ Cr.)
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity13151991782827
Cash from Investing Activity-11-3-19-13-1-17-19
Cash from Financing Activity-2-11-1-6-21-7-8-9
Net Cash Flow01-03-103-2
Free Cash Flow1111187156813
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit80%104%127%62%83%49%102%88%
JENBURPH shareholding pattern (%)
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters46.69%46.68%46.67%46.66%46.65%46.64%46.62%46.62%
DIIs0.12%0.12%0.12%0.12%0.12%0.12%0.12%0.03%
Public53.20%53.20%53.21%53.22%53.24%53.24%53.27%53.34%
No. of Shareholders6,9016,9876,7126,8557,1636,9997,1037,351
JENBURPH key ratios
CategoryMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6855474545505053
Inventory Days991209211592103109154
Days Payable66585683677510091
Cash Conversion Cycle1011178377707859115
Working Capital Days3532171631363141
ROCE %37%26%24%26%27%26%27%27%
JENBURPHUpdated 11 Nov 2026, 0:33

Jenburkt Pharmaceutical L

Market Cap

₹421Cr.

Current Price

₹954

High / Low

₹1,297/845

Stock P/E

11.8

ROE20.2%
ROCE27.0%
Book Value₹464
Face Value₹10.0
Dividend Yield2.17%

About

Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products[1]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Sep 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios
CategoryMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days322332406855474545505053
Inventory Days10710912873991209211592103109154
Days Payable5444724466585683677510091
Cash Conversion Cycle858889691011178377707859115
Working Capital Days-11610253532171631363141
ROCE %42%40%39%42%37%26%24%26%27%26%27%27%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of JENBURKT PHARMACEUTICAL L (JENBURPH)?

The reported market capitalisation for JENBURKT PHARMACEUTICAL L (JENBURPH) is ₹421Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of JENBURPH?

The current price shown for JENBURKT PHARMACEUTICAL L (JENBURPH) on Fincrux is ₹954 with a 52-week high/low of ₹1,297/845.

What is the P/E ratio of JENBURKT PHARMACEUTICAL L (JENBURPH)?

The stock P/E for JENBURKT PHARMACEUTICAL L (JENBURPH) is 11.8 on Fincrux, with ROE at 20.2% and ROCE at 27.0%.

What were JENBURPH latest quarterly results?

For Sep 2026, JENBURKT PHARMACEUTICAL L (JENBURPH) reported sales ₹48 Cr and net profit ₹10 Cr (figures in ₹ crore unless noted).

What are JENBURPH annual sales and net profit?

For TTM, JENBURKT PHARMACEUTICAL L (JENBURPH) shows sales of ₹171 Cr and net profit of ₹33 Cr on the Fincrux profit & loss statement.

Who owns JENBURKT PHARMACEUTICAL L (JENBURPH)?

Latest shareholding for JENBURKT PHARMACEUTICAL L (JENBURPH) on Fincrux: Promoters 46.62% (Sep 2026), DIIs 0.03% (Sep 2026), Public 53.34% (Sep 2026), No. of Shareholders 7,351% (Sep 2026).

Where can I find JENBURKT PHARMACEUTICAL L (JENBURPH) financials?

JENBURKT PHARMACEUTICAL L (JENBURPH) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show JENBURPH balance sheet and cash flow?

Yes. The JENBURKT PHARMACEUTICAL L (JENBURPH) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.